Vindesine in the treatment of malignant mesothelioma: A phase II study

D. Kelsen; R. Gralla; E. Cheng; N. Martini

Vindesine in the treatment of malignant mesothelioma: A phase II study

D. Kelsen, R. Gralla, E. Cheng, N. Martini

Medicine

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Vindesine (VDS) is a new semisynthetic vinca alkaloid which has demonstrated therapeutic activity against a variety of solid tumors. A phase II trial of this agent was performed in patients with advanced malignant mesothelioma. VDS at a dose of 3 mg/m² was given iv once weekly for 4-6 weeks and then every 2 weeks thereafter. Only one of 17 evaluable patients had a partial remission, lasting 5 months (95% confidence limits, 0%-17%). Toxic effects of VDS included leukopenia, peripheral neuropathy, and alopecia. VDS has minimal activity in malignant mesothelioma.

Original language	English (US)
Pages (from-to)	821-822
Number of pages	2
Journal	Cancer Treatment Reports
Volume	67
Issue number	9
State	Published - Jan 1 1983

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{886e5022263746fc9e68ec2e403d1d69,

title = "Vindesine in the treatment of malignant mesothelioma: A phase II study",

abstract = "Vindesine (VDS) is a new semisynthetic vinca alkaloid which has demonstrated therapeutic activity against a variety of solid tumors. A phase II trial of this agent was performed in patients with advanced malignant mesothelioma. VDS at a dose of 3 mg/m2 was given iv once weekly for 4-6 weeks and then every 2 weeks thereafter. Only one of 17 evaluable patients had a partial remission, lasting 5 months (95% confidence limits, 0%-17%). Toxic effects of VDS included leukopenia, peripheral neuropathy, and alopecia. VDS has minimal activity in malignant mesothelioma.",

author = "D. Kelsen and R. Gralla and E. Cheng and N. Martini",

year = "1983",

month = jan,

day = "1",

language = "English (US)",

volume = "67",

pages = "821--822",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Vindesine in the treatment of malignant mesothelioma

T2 - A phase II study

AU - Kelsen, D.

AU - Gralla, R.

AU - Cheng, E.

AU - Martini, N.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Vindesine (VDS) is a new semisynthetic vinca alkaloid which has demonstrated therapeutic activity against a variety of solid tumors. A phase II trial of this agent was performed in patients with advanced malignant mesothelioma. VDS at a dose of 3 mg/m2 was given iv once weekly for 4-6 weeks and then every 2 weeks thereafter. Only one of 17 evaluable patients had a partial remission, lasting 5 months (95% confidence limits, 0%-17%). Toxic effects of VDS included leukopenia, peripheral neuropathy, and alopecia. VDS has minimal activity in malignant mesothelioma.

AB - Vindesine (VDS) is a new semisynthetic vinca alkaloid which has demonstrated therapeutic activity against a variety of solid tumors. A phase II trial of this agent was performed in patients with advanced malignant mesothelioma. VDS at a dose of 3 mg/m2 was given iv once weekly for 4-6 weeks and then every 2 weeks thereafter. Only one of 17 evaluable patients had a partial remission, lasting 5 months (95% confidence limits, 0%-17%). Toxic effects of VDS included leukopenia, peripheral neuropathy, and alopecia. VDS has minimal activity in malignant mesothelioma.

UR - http://www.scopus.com/inward/record.url?scp=0020589022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020589022&partnerID=8YFLogxK

M3 - Article

C2 - 6883358

AN - SCOPUS:0020589022

SN - 0361-5960

VL - 67

SP - 821

EP - 822

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 9

ER -

Vindesine in the treatment of malignant mesothelioma: A phase II study

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this